Evaluation of dual versus triple therapy by landmark analysis in the RE-DUAL PCI trial
BE Peterson, DL Bhatt, P Gabriel Steg… - Cardiovascular …, 2021 - jacc.org
Objectives The aim of this study was to explore the early versus late benefits and risks of
dabigatran dual therapy versus warfarin triple therapy in the RE-DUAL PCI (Randomized …
dabigatran dual therapy versus warfarin triple therapy in the RE-DUAL PCI (Randomized …
Dual Anti-Thrombotic Therapy With Dabigatran After Percutaneous Coronary Intervention in Atrial Fibrillation―Japanese and East-Asian Subgroup Analysis of the RE …
J Ako, K Okumura, K Nakao, K Kozuma, Y Morino… - Circulation …, 2019 - jstage.jst.go.jp
Background: In the RE-DUAL PCI trial, dual anti-thrombotic therapy with dabigatran and a
P2Y 12 inhibitor had a lower risk of bleeding and similar risk reduction of thromboembolic …
P2Y 12 inhibitor had a lower risk of bleeding and similar risk reduction of thromboembolic …
Switching of oral anticoagulation therapy after PCI in patients with atrial fibrillation: the RE-DUAL PCI trial subanalysis
Objectives The aim of this study was to assess if prior oral anticoagulant agent (OAC) use
modifies the lower bleeding risk observed with dabigatran dual therapy (dabigatran twice …
modifies the lower bleeding risk observed with dabigatran dual therapy (dabigatran twice …
The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a …
Abstract Background The RE‐DUAL PCI trial demonstrated that in patients with nonvalvular
atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), dual therapy …
atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), dual therapy …
Design and rationale of the RE‐DUAL PCI Trial: a prospective, randomized, phase 3b study comparing the safety and efficacy of dual antithrombotic therapy with …
Antithrombotic management of patients with atrial fibrillation (AF) undergoing coronary
stenting is complicated by the need for anticoagulant therapy for stroke prevention and dual …
stenting is complicated by the need for anticoagulant therapy for stroke prevention and dual …
[HTML][HTML] Comparison of the effect of age (< 75 Versus≥ 75) on the efficacy and safety of dual therapy (Dabigatran+ Clopidogrel or Ticagrelor) versus triple therapy …
The RE-DUAL PCI trial reported that dabigatran dual therapy (110/150 mg twice daily, plus
clopidogrel or ticagrelor) reduced bleeding events versus warfarin triple therapy (warfarin …
clopidogrel or ticagrelor) reduced bleeding events versus warfarin triple therapy (warfarin …
Effect of lesion complexity and clinical risk factors on the efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after …
Background: The REDUAL PCI trial (Evaluation of Dual Therapy With Dabigatran vs Triple
Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting) demonstrated …
Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting) demonstrated …
[HTML][HTML] Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial …
Background Little is known about the optimal antithrombotic therapy in patients with atrial
fibrillation undergoing PCI for ST-elevation myocardial infarction (STEMI). Aims The aim of …
fibrillation undergoing PCI for ST-elevation myocardial infarction (STEMI). Aims The aim of …
Dabigatran dual therapy versus warfarin triple therapy post–PCI in patients with atrial fibrillation and diabetes
Objectives The aim of this study was to evaluate dabigatran dual therapy versus warfarin
triple therapy in patients with or without diabetes mellitus in the RE-DUAL PCI (Randomized …
triple therapy in patients with or without diabetes mellitus in the RE-DUAL PCI (Randomized …
Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous …
GYH Lip, L Mauri, G Montalescot, M Ozkor… - American Heart …, 2019 - Elsevier
Background In the RE-DUAL PCI trial of patients with atrial fibrillation (AF) who underwent
percutaneous coronary intervention (PCI), dabigatran dual therapy (110 or 150 mg bid, plus …
percutaneous coronary intervention (PCI), dabigatran dual therapy (110 or 150 mg bid, plus …